Tumor Steatosis and Glutamine Synthetase Expression in Patients with Advanced HCC Receiving Atezolizumab plus Bevacizumab Therapy.

Yutaka KurebayashiHanako TsujikawaKatsutoshi SugimotoDaisuke YunaiyamaYoichi ArakiKazuhiro SaitoHiroshi TakahashiTatsuya KakegawaTakuya WadaYusuke TomitaMasakazu AbeYu YoshimasuHirohito TakeuchiTaiki HirataKentaro SakamakiKazuhiro KakimiToshitaka NagaoTakao ItoiMichiie Sakamoto

Published in: Hepatology research : the official journal of the Japan Society of Hepatology (2023)

The biology and TIME of HCC were strikingly different in advanced HCC compared with those of surgically resected HCC. Two metabolism-related factors, pathologically-determined tumor steatosis and/or GS expression, and MRI-determined tumor steatosis, were found to be the most significant prognostic indicators for Atezo+Bev therapy in advanced HCC. This article is protected by copyright. All rights reserved.

Keyphrases

insulin resistance
poor prognosis
high fat diet
magnetic resonance imaging
stem cells
type diabetes
computed tomography
adipose tissue
contrast enhanced
mesenchymal stem cells
long non coding rna
cell therapy
diffusion weighted imaging